Supreme Court Amicus Brief Regarding Wyeth V. Diana Levine
28 Pages Posted: 11 Jun 2008 Last revised: 24 Jul 2008
Date Written: June 2008
Abstract
Prominent in arguments opposing preemption of state tort law liability for alleged inadequacies in prescription drug labeling is the argument that such liability can complement FDA regulation by improving on a regulatory scheme that fails to provide adequate deterrence against the marketing of unsafe or inadequately labeled drugs. The premise of this argument is faulty. Fundamental principles of economics and numerous studies of FDA drug regulation reveal that FDA in fact errs on the side of overregulation of prescription drugs. Product liability litigation focused solely on one side of the prescription drug public health equation leads to further distortions of the drug approval and labeling process and exacerbates FDA's inherent overly cautious approach. Preemption of state tort law where it conflicts with FDA requirements will minimize these distortions and thereby maximize public health.
Suggested Citation: Suggested Citation
Do you have a job opening that you would like to promote on SSRN?
Recommended Papers
-
Product Liability versus Reputation
By Juan-josé Ganuza, Fernando Gomez-pomar, ...
-
The Easy Case for Products Liability: A Response to Professors Polinsky and Shavell
-
Markets with Untraceable Goods of Unknown Quality: A Market Failure Exacerbated by Globalization
By Timothy J. Mcquade, Stephen W. Salant, ...
-
Equilibrium and Welfare in a Model of Torts with Industry Reputation Effects
By Andrzej Baniak and Peter Grajzl